CD8 CD28 Regulatory T Cells After Induction Therapy Predict Progression-free Survival in Myeloma Patients: Results from the GMMG-HD6 Multicenter Phase III Study
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Dhodapkar M, Krasovsky J, Olson K
. T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells. Proc Natl Acad Sci U S A. 2002; 99(20):13009-13.
PMC: 130577.
DOI: 10.1073/pnas.202491499.
View
2.
Raja K, Rihova L, Zahradova L, Klincova M, Penka M, Hajek R
. Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma. PLoS One. 2012; 7(10):e47077.
PMC: 3468567.
DOI: 10.1371/journal.pone.0047077.
View
3.
Collins S, Bakan C, Swartzel G, Hofmeister C, Efebera Y, Kwon H
. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunol Immunother. 2013; 62(12):1841-9.
PMC: 4134870.
DOI: 10.1007/s00262-013-1493-8.
View
4.
Pazina T, James A, Colby K, Yang Y, Gale A, Jhatakia A
. Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma. Cancer Immunol Res. 2019; 7(10):1633-1646.
PMC: 6774869.
DOI: 10.1158/2326-6066.CIR-18-0579.
View
5.
Usmani S, Hoering A, Ailawadhi S, Sexton R, Lipe B, Hita S
. Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial. Lancet Haematol. 2020; 8(1):e45-e54.
PMC: 8601389.
DOI: 10.1016/S2352-3026(20)30354-9.
View